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Traditional preclinical studies of cancer therapeutics have relied on the use of established 
human cell lines that have been adapted to grow in the laboratory and, therefore, may 
deviate from the cancer they were meant to represent. With the emphasis of cancer 
drug development shifting from non-specific cytotoxic agents to rationally designed 
molecularly targeted therapies or immunotherapy comes the need for better models with 
predictive value regarding therapeutic activity and response in clinical trials. Recently, 
the diversity and accessibility of immunodeficient mouse strains has greatly enhanced 
the production and utility of patient-derived xenograft (PDX) models for many tumor 
types, including non-small cell lung cancer (NSCLC). Combined with next-generation 
sequencing, NSCLC PDX mouse models offer an exciting tool for drug development and 
for studying targeted therapies while utilizing patient samples with the hope of eventually 
aiding in clinical decision-making. Here, we describe NSCLC PDX mouse models gen-
erated by us and others, their ability to reflect the parental tumors’ histomorphological 
characteristics, as well as the effect of clonal selection and evolution on maintaining 
genomic integrity in low-passage PDXs compared to the donor tissue. We also raise vital 
questions regarding the practical utility of PDX and humanized PDX models in predicting 
patient response to therapy and make recommendations for addressing those ques-
tions. Once collaborations and standardized xenotransplantation and data management 
methods are established, NSCLC PDX mouse models have the potential to be universal 
and invaluable as a preclinical tool that guides clinical trials and standard therapeutic 
decisions.
Keywords: patient-derived xenograft, lung cancer, personalized medicine, precision medicine, preclinical trial
iNtrODUctiON
In 1969, Rygaard and Povlsen reported successful serial passages of a malignant sigmoid colon 
carcinoma implanted subcutaneously into nude mice. Histological integrity was maintained during 
the transfers with regard to degree of differentiation, stromal components, and mucoid production 
compared to that of the primary tumor (1). This was the first reported human solid tumor PDX in 
FiGUre 1 | Personalized medicine clinical trial approach with 
PDX models. Genomic analysis of a patient tumor identifies potential 
therapeutically targetable mutations. Rationally chosen molecularly targeted 
agents against the identified driver mutation are tested in PDX models 
generated from the patient sample. The most promising agent could be 
administered to the patient, usually at the time of tumor recurrence or initial 
treatment failure. The treatment outcome and preclinical trial data are banked 
in order to inform future studies.
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mice. Since then, the variety and availability of immunodeficient 
host strains has greatly increased, leading to improved tumor 
engraftment rates and the subsequent widespread use of PDX 
mouse models in academia and industry.
PDX mouse models can potentially be used to (i) gain a better 
understanding of cancer biology, (ii) investigate novel anticancer 
treatments while considering both a patient-derived tumor tissue 
and an in vivo setting, (iii) study biomarkers of therapy response 
and resistance, and (iv) develop personalized therapeutic 
regimens (2–4) [reviewed in Ref. (5, 6)]. The recent popularity 
of PDX models has paralleled advances in high-throughput 
next-generation sequencing, which has provided a window into 
the complexities of human cancer and demonstrated the need 
to distinguish driver alterations from passenger events within 
the heavy mutational load. Subsequent characterization of the 
landscape of genetic mutations and copy number variations has 
facilitated the identification of “druggable” driver mutations. A 
number of novel drugs that target oncogenic drivers have been 
developed and entered the clinic. However, this development was 
limited in part by the use of human cancer cell lines that had been 
propagated in the laboratory for decades, resulting in major and 
irreversible biological changes, including gain or loss of genetic 
information, metastatic ability, and stem cell populations, which 
leads to divergence from the tumor they were meant to represent 
(5, 7–9), compromising their predictive value with regards to 
therapeutic activity. The recent collection and utilization of large 
PDX tumor banks has offered an exciting tool for potentially 
maximizing the efforts and ultimate success of drug development 
given their ability to represent and maintain biological integrity 
and tumor heterogeneity present in the clinic due to their lack 
of in vitro culture and low-passage xenoengraftment. Clinically 
and molecularly annotated PDXs that fit within defined genetic 
subsets could potentially be procured from various sources 
and used to predict the response of patient tumors with similar 
genetic backgrounds, providing an effective resource to aid in 
identification of chemoresponsive biomarkers and subsequently 
target patient populations. As a clinically representative tool that 
best recapitulates the biological properties of their respective 
tumor type, PDX mouse models could serve as an important 
aid in personalized medicine studies as well. Specifically, PDXs 
could be used as part of co-clinical trials, whereby the model 
and patient are treated simultaneously (5, 6). Similarly, preci-
sion medicine-directed clinical trials could utilize PDX models, 
whereby the xenografted animals are treated with rationally 
chosen targeted therapies and the most effective option is given to 
the patient, usually in the setting of tumor recurrence or after the 
initial therapy proved ineffective (Figure  1). These approaches 
of tailoring cancer therapy based on PDX models could lead to 
better informed treatment decisions, which potentially increases 
the success rate of clinical trials and ultimately patient care.
PAtieNt-DeriveD XeNOGrAFt MODeLs 
OF NON-sMALL ceLL LUNG cANcer 
(NscLc)
Despite substantial improvements in early detection procedures 
and targeted therapies, lung cancer is still the leading cause of 
cancer-related deaths worldwide (10). Front-line treatment of 
patients with advanced NSCLC historically consisted of radia-
tion and/or standard systemic chemotherapeutic drugs, such as 
carboplatin and paclitaxel. Recently, the discovery of “actionable” 
genetic alterations has resulted in the development of targeted 
therapeutic agents. In particular, the identification of muta-
tions in the gene encoding epidermal growth factor receptor 
(EGFR) in NSCLC patients with adenocarcinoma has led to the 
utilization of small-molecule tyrosine kinase inhibitors, such as 
gefitinib or afatinib specifically for that subtype of patients (11). 
Moreover, patients with translocations involving the anaplastic 
lymphoma kinase (ALK) can be treated with ALK inhibitors, 
such as crizotinib or ceritinib (12, 13). Additionally, crizotinib 
has also been shown to be effective in advanced NSCLC patients 
with ROS1 translocations (14). Consequently, according to the 
College of American Pathologists, the International Association 
for the Study of Lung Cancer, and the Association of Molecular 
Pathologists, it is recommended that, whenever feasible, all 
advanced NSCLC patients with elements of the adenocarcinoma 
histological subtype should be screened for EGFR mutations and 
ALK fusions in order to guide therapy selection (15). Immune 
checkpoint inhibitors that target either PD-1 or PD-L1 have also 
proven effective. Based on the data from a seminal trial (16), 
a monoclonal antibody targeting PD-1, pembrolizumab, has 
recently been approved by the US Food and Drug Administration 
for use as a front-line therapy for advanced NSCLC patients 
without activating EGFR mutations or ALK fusions, but express-
ing PD-L1. Additional therapeutic agents, including compounds 
tABLe 1 | Histological and genetic features of lung tumors and PDXs.
iD subtype Patient tumor PDX
Differentiation Gene Mutation Frequency Differentiation Gene Mutation Frequency
T-009 SCCc Moderate SMO S354L 0.11 Small cellb None None
FGFR1 D161N 0.10
SMAD4 R531Q 0.07
T-020 ADCd Moderate SMO V411A 0.06 Moderate None None
AKT1 R25H 0.08
CDH1 T406A 0.06
T-025 ADCd Moderate–well KIT V530I 0.13 Small cellb None None
T-035 SCCc Poor None None Poor ATM R1768L 0.07
ATM S1947F 0.06
T-042 ADCd Moderate TP53 R273L 0.16 Poor TP53 R273L 0.99
T-050 SCCc Poor PIK3CA Q452L 0.13 Poor PIK3CA Q452L 0.15
TP53 V274L 0.08
T-054 ADCd Moderate KRAS G12V 0.11 Poor KRAS G12V 0.30
T-065 SCCc Moderatea FLT3 A680V 0.67 Moderate FLT3 A680V 0.95
GNA11 V359A 0.06
T-067 SCCc Poor MET L1243I 0.16 Poor MET L1243I 0.20
TP53 V274L 0.56 TP53 V274L 0.99
NOTCH1 A1701T 0.06
aThe evaluation of tumor grade was from a PDX that was passaged once in a mouse.
bThe tumor phenotype transformed into a histology consistent with small cell carcinoma.
cSCC indicates squamous cell carcinoma.
dADC indicates adenocarcinoma.
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that could target oncogenic alterations in KRAS, PIK3CA, AKT1, 
or HER2, as well as MET amplification and RET fusions, are being 
actively developed and tested. It is expected that PDX models 
from primary or metastatic NSCLC tumors will facilitate the 
preclinical testing of these new compounds, which may hasten 
their potential usage in the clinic.
Primary or metastatic NSCLC tumors have been utilized to 
establish orthotopic or heterotopic (subcutaneous, subrenal 
capsule) PDX murine models from multiple labs, with reported 
engraftment rates ranging between 23 and 90% (2, 3, 17–20). 
Moreover, NSCLC PDXs have been generated by consortium 
members of the EurOPDX,1 PRoXe (21),2 the NCI,3 and the 
Jackson Laboratory,4 as well as by for-profit companies, includ-
ing Champions Oncology, Novartis (22), and OncoMed 
Pharmaceuticals, among others. In general, squamous cell 
carcinoma has demonstrated a higher engraftment rate than 
adenocarcinoma (17, 18). Specifically, Russo’s group determined 
that PDXs derived from adenocarcinoma had decreased Ki67 
staining and lower expression of stem-cell-related genes (SOX2 
and ALDH1A1), which could contribute to the reduced engraft-
ment success (17). The utility of PDX models for human NSCLC 
depends on the precise reflection of the parental tumors’ patho-
logic and molecular characteristics. Overall, early-passage PDXs 
retained many of the mutations or allele frequencies that were 
present in the original tumor (2, 18, 20, 22). Most of the studies 
documented that the PDXs had preserved morphological (2, 3, 
19, 20) and immunohistochemical (2, 3, 20) features compared to 
1 http://europdx.eu/pdx-collection.html
2 https://proxesite.wordpress.com/
3 https://dtp.cancer.gov/organization/btb/tumor_repositories.htm
4 https://www.jax.org
the donor tissue; however, Russo’s group reported that only 60% 
of the xenografts retained the original tumor morphology at all 
harvesting points. Specifically, the loss of preserved morphology 
was observed mainly in adenocarcinoma PDXs that lost their 
tumor epithelial component within 3 months after engraftment 
(17). As has been previously reported for numerous other tumor 
types, established NSCLC PDXs have lost the human stroma 
and immune cells after repeated passages as well (2, 5, 9, 23, 
24). Depletion of human-derived tumor-associated cells within 
NSCLC PDXs was corroborated in gene expression studies that 
revealed a downregulation of genes corresponding to cell adhe-
sion and immune response pathways (2).
We have generated a PDX tumor bank from NSCLC patient 
samples collected through the Rutgers Cancer Institute of New 
Jersey Biospecimen Repository Service and approved by the 
Institutional Review Board (IRB) of Rutgers University. We 
 successfully produced 20 PDX models from 66 lung tumors 
(30% success rate) by means of passaging and expansion through 
subcutaneous engraftment in NOD scid gamma (NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ) mice. The animal protocol was approved 
by the Institutional Animal Care and Use Committee of Rutgers 
University. In order to characterize and validate our PDX models, 
we selected nine matched pairs of primary tumors and their 
corresponding PDXs (at passage three or four) (four adenocarci-
noma and five squamous cell carcinoma) to undergo histological 
evaluation and next-generation sequencing.
Microscopic examination of hematoxylin and eosin (H&E)-
stained formalin-fixed paraffin-embedded tissues by a board cer-
tified pathologist revealed that the tumor cells from the majority 
of the early-passage PDXs maintained the morphological features 
of NSCLC, except for two PDX tumors that transformed into a 
small cell carcinoma histology (Table  1). Overall, there was a 
4Morgan et al. Lung Cancer Patient-Derived Xenograft Models
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trend toward higher histologic grade in the PDXs compared to the 
parental tumor. Specifically, out of the six lung tumors that were 
moderately to well differentiated, four became poorly differenti-
ated or transformed to small cell histology after minimal murine 
passages (Table 1). This may be attributed to clonal selection and 
the loss of tumor heterogeneity, as well as the reduction of human 
stromal components upon passaging through mice. In every case, 
there was a substantial decrease or loss of human-derived tumor 
stroma and accessory cells, including normal lung parenchyma, 
vasculature, immune cells, and fibroblasts.
Utilizing our panel of matched pairs of primary tumors and 
their corresponding PDXs, we PCR-enriched the genomic DNA 
for known mutational hotspots in 50 cancer genes using the 
ThunderBolts Cancer Panel v7.1 (RainDance Technologies) and 
then sequenced the targeted DNA on a MiSeq System (Illumina, 
Inc.) to a coverage of at least 500×. Alignment and variant calling 
were performed using BaseSpace with default parameters. The 
variants were filtered using VarSeq (Golden Helix) to exclude all 
synonymous or benign mutations and to exclude variants with 
less than 5% minor allele frequency. Only two (T-042 and T-054) 
of the nine matched pairs had the same mutations detected in 
both the patient tumor tissue and the low-passage PDX (Table 1). 
Furthermore, out of the 14 total mutations detected in the primary 
tumors, only 6 (43%) were detected in the corresponding PDXs. 
Four additional mutations arose in the early passage PDXs that 
were not detected in the parental tumor. We examined the raw 
sequence reads and confirmed the absence of the mutations in 
the corresponding primary tumors. These data suggest that clonal 
selection and evolution occur early on when human tumors are 
propagated in mice. Additionally, the majority of mutations that 
were detected in both the patient tumors and PDXs had higher 
mutant allele frequencies in the PDX compared to the donor 
tissue. These differences may be attributed to loss of stroma and 
thus an enrichment of tumor cells in the PDX as compared to the 
primary sample or, in the case of TP53 in T-042 and T-067, a loss 
of heterozygosity. An assessment of the percentage of tumor cells 
in each sample by the pathologist indicated that the increased 
allele frequencies in the PDX tumors could at least partially be 
attributed to the increase in tumor cells. The estimated percentage 
of tumor cells within the primary tumors ranged from 20 to 80% 
(mean, 59%), whereas the estimated percentages of tumor cells 
within the PDXs were all “>90%,” with the exception of T-054, 
which had 60% tumor cells. However, the observed increase in 
allele frequencies in the PDXs might also be attributed to clonal 
selection. This evidence for clonal evolution occurring early 
during passaging in mice needs to be addressed systematically, 
and the consequence of such evolution on response to targeted 
therapy needs to be fully defined.
PAtieNt-DeriveD XeNOGrAFts 
As PrecLiNicAL MODeLs FOr 
PersONALiZeD MeDiciNe
While many of the NSCLC PDX model studies have utilized sub-
cutaneous implantation for xenoengraftment (2, 18, 25), others 
have focused on orthotopic sites (19, 26) or the well-vascularized 
subrenal capsule (3, 17). When compared to the subcutaneous 
model, orthotopic implantation may maintain improved tumor 
integrity and demonstrate more phenotypic characteristics, such 
as metastasis development, but the models have not been directly 
compared to address if one is a better predictor of response to 
therapy (5, 27, 28). Moreover, while orthotopic transplantation 
may more accurately mimic the parental tumors by virtue of 
replicating aspects of the native microenvironment, this method 
is technically challenging, labor intensive, and expensive (5), 
which could impede its universal implementation and, thus, its 
ultimate utility in preclinical modeling. Recently, an area of active 
investigation has been the humanized mouse xenograft model, 
where immune cells, such as hematopoietic stem cells from 
cord blood or matched from the donor, are co-transplanted into 
immunodeficient mice along with patient tumor tissue (29). Such 
models will be needed to test the efficacy of immunotherapy or 
to study antitumor immunity as well as the involvement of the 
immune system in responsiveness to chemotherapy.
Overall, the ability of primary samples to engraft is still 
suboptimal and a PDX cannot be created for every patient (2, 5, 
18, 19, 27). Additionally, the high cost and the amount of time 
needed for implantation, expansion, and drug testing renders 
prospective co-clinical trials using patient-centric mouse avatars 
less suitable for use in real-time therapeutic decision-making, 
especially for patients with advanced or aggressive tumors (5, 6, 
9, 25). However, PDX models have the potential to be immensely 
valuable in preclinical trials whereby the data will be used to 
guide therapeutic decisions for future patients. Consequently, in 
the near future, PDX models might serve best as excellent tools 
for co-clinical trials only in certain circumstances.
On the other hand, PDX models can be used retrospectively 
to identify therapeutic recommendations for patients who have 
molecular characteristics similar to those of the donor patient 
from whom the xenograft was derived (5, 27). Collaborations 
between groups and networks have been, and should continue 
to be, developed in which existing PDX model material and data 
are gathered and shared (Figure 1). For such interactions to be 
productive, the cataloged information should be derived from 
standardized xenotransplantation methods, sample validation 
and data collection procedures, nomenclature, banking of genetic 
and histomorphological characterization, therapeutic response 
or resistance reporting, and so on, such that the resource provides 
all necessary information to obtain the best possible match for 
the current patient being treated in the clinic. This is imperative 
given the fact that even morphologically similar cancers are 
exceedingly heterogeneous at the genomic level, while subject to 
a unique interplay with stromal components and additional cells 
found in the tumor microenvironment, which may influence the 
response to treatment. The EurOPDX Consortium (5) as well as 
the NCI Patient-Derived Models Repository can serve as proto-
types for this initiative as they demonstrate how to successfully 
bring together multi center translational and clinical researchers 
to standardize sample processing and data collection to create 
a network of annotated PDX models with the primary goal of 
collaborating on preclinical and co-clinical trials.
To maximize the utility of a PDX model database to inform 
treatment options, it is well understood that contributors 
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would ideally distribute requested models to investigators for 
drug testing, while reporting all regimens previously evalu-
ated. However, to be translational, the preclinical standards 
of success would need to be aligned with the criteria used 
in the clinic. For example, a statistically significant tumor 
growth reduction of 70% compared to untreated mice in a 
preclinical experiment would be seen as 30% tumor growth 
during treatment in the clinical setting, which is considered 
progressive disease and treatment failure. Success in patient 
care is represented by stable disease or regression (24, 27). In 
addition, we need to take into account the differences in drug 
metabolism and pharmacokinetics between a mouse versus 
a human (30). Futhermore, we should keep in mind that the 
majority of preclinical studies utilize weight-adjusted therapy 
dosages, while the assessment of drugs at clinically achievable 
exposures would be better at predicting clinical efficacy (27). 
In general, it must be remembered that PDXs are models. They 
are only representations of the real life situation. This notion 
is often forgotten when the findings are extrapolated to more 
general conclusions (27) or, as it pertains here, when data from 
preclinical studies utilizing PDX models is translated in the 
clinic, often resulting in expensive failures and hasty dismissal 
of potentially informative data.
An outstanding question in the field is whether or not PDXs 
must maintain the histopathological and molecular characteristics 
of the parental tumor to be reliable preclinical models. Our data 
presented here and the work of others have shown that generation 
of a PDX model in a murine host leads to clonal selection (18, 23, 
27), which may eventually result in a xenograft that differs from 
the original patient’s tumor. However, the selection of “stronger” 
clonal subpopulations may represent genetic changes that 
would eventually occur in the primary lesion, particularly after 
chemo- and/or radiotherapy, and contribute to tumor survival, 
metastasis, and targeted treatment efficacy (5, 6, 9, 23), making 
the utility of these PDX models still viable. One way to test this is 
to directly compare the genomic landscape between low-passage 
PDXs and tumor biopsies obtained from a large cohort of patients 
who have recurrent disease after standard therapy.
In addition to clonal selection, our data and studies reported 
by others have demonstrated that even in early murine passages, 
PDX human stromal elements (including cancer-associated 
fibroblasts, endothelial cells, as well as immune and inflammatory 
cells) are lost (2, 5, 9, 23). In general, all PDXs will eventually 
lose the human stromal elements. Thus, the consensus is that 
a low-passage number is ideal to conserve histological and 
genetic integrity of the primary tumor (6, 9). However, given 
that the speed and extent with which this transition from human 
stroma to murine stroma occurs is still controversial and may 
be tumor-specific, it is unknown which low passage is the magic 
number. To combat this loss of stromal components through 
xenoengraftment, some researchers have taken to using sup-
plemental support matrix, such as Matrigel, or coimplantation 
of patient-matched fibroblasts, which may improve survival of 
neoplastic cells and, thus, engraftment rate of implanted tumor 
samples (23, 27). Similarly, patient-matched humanized PDX 
models with coengrafted stromal and immune components along 
with the donor tumor tissue (23, 29), while expensive and labor 
intensive for general use, may allow researchers and clinicians to 
both predict and explain tumor response to therapy in instances 
where the tumor–stroma and tumor–immune interactions must 
be taken into account.
There is a general consensus that the technical and logistical 
challenges need to be fully addressed before PDX model systems 
can be universally utilized to inform clinical decision-making. 
Any changes in the tumor microenvironment and clonal 
selection that occurs through xenotransplantation must be 
considered, measured, and factored into the experimental find-
ings. While PDX models do not perfectly mimic all aspects of 
human cancer, they are a valuable tool for evaluation of targeted 
therapies and elucidation of biomarkers for predictive treatment 
response.
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